CATUG Opens Global HQ in Basel to Drive mRNA & Gene Therapy Innovation

Basel, Switzerland, September 26, 2024 — CATUG, a RNA and genetic therapy focused Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), is proud to announce the establishment of its new global headquarters (CATUG AG) in Basel, Switzerland. This marks a pivotal moment in CATUG's expansion, positioning the company at the forefront of the biotech and life sciences industry, where it will continue to accelerate the development of groundbreaking RNA and genetic therapies.

 Why Basel? A Strategic Choice for Both Growth and Innovation

Situated at the heart of Europe, Basel provides CATUG with proximity to key European markets, enhancing business operations and partnerships. Basel’s favorable economic conditions offer a supportive environment for long-term growth and expansion.

"Our move to Basel is driven by the region’s unmatched potential for collaboration, innovation, and growth," said Dr. Lin Jin, president of CATUG AG. "This new global headquarters reinforces our mission to drive the future of new modality medicine, where excellence in innovation leads to transformative healthcare solutions."

As a major biotech hub, Basel offers a wealth of opportunities for growth and collaboration. The region’s strong life science cluster, combined with Switzerland’s business-friendly environment and access to world-class universities and research institutions, makes Basel the ideal location for CATUG’s next level of innovation. The availability of industry events, conferences, and networking opportunities will further foster CATUG’s connections within the biotech community, allowing the company to stay at the cutting edge of research and development.

Great Ecosystem and Local Support

As part of this expansion, CATUG AG has partnered with the Swiss Innovation Park (SIP) and established its first office on the SIP Novartis Campus. This collaboration offers CATUG access to a vibrant innovation ecosystem and strengthens its ability to foster cutting-edge developments in nucleic acid therapeutics.

"Basel provides the perfect environment for our global HQ, thanks to its strong biotech ecosystem and local support," added by Lin. "We greatly appreciate local partners and organizations, especially SIP Basel Area that offered professional support and seamless service for our set up. We also believe the region’s collaborative environment and abundant funding opportunities will play a crucial role in fueling our growth and technological innovation."

"We are excited to welcome CATUG to the Swiss Innovation Park, particularly at our prestigious Novartis Campus," said Rahel Schneider, Community Manager and Site Development at SIP. "CATUG’s leadership in RNA and gene therapy as contract service provider aligns perfectly with the synergy of our biotech ecosystem at SIP. We look forward to supporting their continued growth and blooming on our campus."

We Keep Looking Up

With cutting-edge technology platforms and state of the art facilities, CATUG positions itself more than just a service provider.

“We’d like to be viewed as a strategic partner to journey together with our Clients from drug discovery and development all the way to patient care,” said Lin. “CATUG’s commitment to quality and compliance is centered with its 4 F operation value: Focus, Fast, First, and Flexible. We’ll keep technology driven and very specific focus in the new modality medicine, with fast delivery, client first attitude, and flexible customized solutions.”

The decision to establish its headquarters in Basel reflects CATUG’s long-term vision of shaping its future through collaboration and innovation. With this move, CATUG is well-positioned to continue its mission of accelerating the development of RNA therapeutics and genetic therapies ensuring these groundbreaking treatments reach patients as efficiently as possible.

About CATUG
CATUG is a specialized Contract Research and Development Manufacturing Organization (CRDMO) and a one-stop solution in nucleic acid-based therapeutics through its leading DNA, RNA, LNP, and analytical platforms. With strong expertise and know-how CATUG aims to provide customized solutions in the life cycle of mRNA therapeutics, gene editing, and gene and cell therapy development. For more detailed information, please visit https://www.catug.bio/